Frequency of human papillomavirus infection and genotype distribution among women with known cytological diagnosis in a Southern Italian region

Journal of Preventive Medicine and Hygiene

Volumn 51, Issue 4, 2010, Pages 139-145

  Chironna, Maria ^a   Neve, A ^a   Sallustio, A ^a   De Robertis, A ^a   Quarto, M ^a   Germinario, C ^a   Lepera, A ^b   Cicinelli, E ^b   Carriero, C ^b   Pinto, V ^b   Miniello, G ^b   Borraccino, V ^b   Blasi, N ^b   Romano, F ^b   Noya, E ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NONE

Author keywords

HPV type distribution; Pap test; Southern Italy

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOLOGY; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ITALY; LUMBAR SPINE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; UTERINE CERVIX CARCINOMA;

ADULT; CHI-SQUARE DISTRIBUTION; CYTODIAGNOSIS; FEMALE; GENOTYPE; HUMANS; ITALY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79953845039     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. WHO 2006. World Health Organization Report: Comprehensive cervical cancer control: a guide to essential practice. Available at: http://www.who.int/ reproductivehealth/publications/cancers/9241547006/en/index.html.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. AIRT Working Group. I tumori in Italia-Rapporto 2006. Incidenza, mortalità e stime. (Tumors in Italy-Report 2006. Incidence, mortality and estimates). Epidemiologia e Prevenzione 2006;30(Suppl. 1):64-5.
4. Walboomers JM, Jacobs MV, Manos MM, et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
5. Mufioz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human Papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
6. Trottier H, Franco EL. The epidemiology of genital human Papillomavirus infection. Vaccine 2006; 24(Suppl. 24): 1-15.
7. Smith JS, Lindsay L, Hoots B, et al. Human Papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
8. Clifford GM, Rana RK, Franceschi S, et al. Human Papilloma-virus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64. (Pubitemid 40656461)
9. Muñoz N, Castellsagué X, de González AB, et al. Chapter I: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl. 3):S1-S10. (Pubitemid 44293019)
10. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human Papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85. (Pubitemid 38924707)
11. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. (Pubitemid 46977438)
12. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66. (Pubitemid 44863348)
13. Stevens MP, Rudland E, Garland SM, et al. Assessment of MagNA pure LC extraction system for detection of human Papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and UNEAR ARRAY HPV tests. J Clin Microbiol 2006;44:2428-33. (Pubitemid 44092407)
14. van Hamont D, van Ham MA, Bakkers JM, et al. Evaluation of the SPF10-INNO LiPA human Papillomavirus (HPV) genotyping test and the Roche linear array HPV genotyping test. J Clin Microbiol 2006;44:3122-9. (Pubitemid 44413740)
15. Masia G, Mazzoleni AP, Contu G, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Sardinia (Italy). Vaccine 2009;27:A 11-A16.
16. Del Prete R, Di Taranto AM, et al. Prevalence and genotypes identification of human Papillomavirus infection in a population of South Italy. J Clin Virol 2008;42:211-4.
17. Rassu M, Bertoloni G, Mengoli C, et al. HPV genotype prevalence in cervical specimens with abnormal cytology: a report from north-east Italy. Scand J Infect Dis 2005;37:476-81. (Pubitemid 41038519)
18. Capra G, Giovannelli L, Bellavia C, et al. HPV genotype prevalence in cytologically abnormal cervical samples from women living in south Italy. Virus Res 2008;133:195-200.
19. Pannier-Stockman C, Segard C, Bennamar S, et al. Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities. J Clin Virol 2008;42:353-60.
20. Evans MF, Adamson CS, Papillo JL, et al. Distribution of human Papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer 2006;106:1054-64.
21. Conesa-Zamora P, Ortiz-Reina S, Moya-Biosca J, et al. Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain. BMC Infect Dis 2009;9:124.
22. Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl. 3):S3/26-34.
23. Lonky NM, Felix JC, Naidu YM, et al. Triage of atypical squamous cells of undetermined significance with hybrid capture II: colposcopy and histologic human Papillomavirus correlation. Obstet Gynecol 2003;101:481-9. (Pubitemid 36288487)
24. Tornesello ML, Duraturo ML, Botti G, et al. Prevalence of alpha-Papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol 2006;78:1663-72. (Pubitemid 44672511)
25. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5. (Pubitemid 36897943)
26. Gargiulo F, De Francesco MA, Schreiber C, et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 2007;125:176-82. (Pubitemid 46613818)
27. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9. (Pubitemid 46333946)
28. Ronco G, Ghisetti V, Segnan N, et al. Prevalence of human Papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005;41:297-305. (Pubitemid 40126963)
29. Ronco G, Brezzi S, Carozzi F, et al. The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecol Oncol 2007;107:S230-2.
30. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
31. Naucler P, Ryd W, Törnberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
32. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.